Chinese Expert Consensus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancies
Yan Li,Yun-Feng Zhou,Han Liang,Hua-Qing Wang,Ji-Hui Hao,Zheng-Gang Zhu,De-Seng Wan,Lun-Xiu Qin,Shu-Zhong Cui,Jia-Fu Ji,Hui-Mian Xu,Shao-Zhong Wei,Hong-Bin Xu,Tao Suo,Shu-Jun Yang,Cong-Hua Xie,Xiao-Jun Yang,Guo-Liang Yang
DOI: https://doi.org/10.3748/wjg.v22.i30.6906
IF: 5.374
2016-01-01
World Journal of Gastroenterology
Abstract:Locoregional spread of abdominopelvic malignant tumors frequently results in peritoneal carcinomatosis (PC). The prognosis of PC patients treated by conventional systemic chemotherapy is poor, with a median survival of < 6 mo. However, over the past three decades, an integrated treatment strategy of cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed by the pioneering oncologists, with proved efficacy and safety in selected patients. Supported by several lines of clinical evidence from phases I, II and III clinical trials, CRS + HIPEC has been regarded as the standard treatment for selected patients with PC in many established cancer centers worldwide. In China, an expert consensus on CRS + HIPEC has been reached by the leading surgical and medical oncologists, under the framework of the China Anti-Cancer Association. This expert consensus has summarized the progress in PC clinical studies and systematically evaluated the CRS + HIPEC procedures in China as well as across the world, so as to lay the foundation for formulating PC treatment guidelines specific to the national conditions of China.